World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
36071
World Ranking
16901
National Ranking
8478

Overview

Ingrid A. Mayer is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on Oncology and related subfields including Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Genetics.

Their main research topics cover a range of areas within cancer study and treatment. These include Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, and Cancer Risks and Factors.

Frequent publication venues for their work include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • Breast Cancer Research and Treatment

Some of the recent papers associated with their research are:

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology (2020), Journal of the National Comprehensive Cancer Network
  • Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1 (2020), Annals of Oncology
  • NCCN Guidelines® Insights: Breast Cancer, Version 4.2021 (2021), Journal of the National Comprehensive Cancer Network
  • Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab (2021), Cancer Discovery
  • Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) (2021), Journal of Clinical Oncology

They frequently collaborate with other researchers in oncology and cancer research. Notable co-authors include:

  • Hope S. Rugo
  • Vandana G. Abramson
  • Lynne I. Wagner
  • Carlos L. Arteaga
  • Sibylle Loibl

Best Publications

  • Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

    Giampaolo Bianchini;Justin M. Balko;Ingrid A. Mayer;Melinda E. Sanders

  • Clinical practice guidelines in oncology

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    William J. Gradishar;Benjamin O. Anderson;Jame Abraham;Rebecca Aft

  • The PI3K/AKT Pathway as a Target for Cancer Treatment.

    Ingrid A. Mayer;Carlos L. Arteaga

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A Mayer;Linda T Vahdat;Sara M Tolaney

  • HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

    David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Breast cancer: Clinical practice guidelines in oncology

    Robert W. Carlson;Benjamin O. Anderson;Harold J. Burstein;Charles E. Cox

  • Resistance to Trastuzumab in Breast Cancer

    Paula R. Pohlmann;Ingrid A. Mayer;Ray Mernaugh

  • NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

    Joseph A. Sparano;Robert J. Gray;Peter M. Ravdin;Della F. Makower;Della F. Makower

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Catherine Van Poznak;Mark R. Somerfield;Robert C. Bast;Massimo Cristofanilli

  • Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    F. André;E.M. Ciruelos;D. Juric;S. Loibl

  • Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results

    Thomas E. Yankeelov;Martin Lepage;Martin Lepage;Anuradha Chakravarthy;Elizabeth E. Broome

  • Invasive breast cancer version 1.2016

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.

    Angel Guerrero-Zotano;Ingrid A. Mayer;Carlos L. Arteaga

Frequent Co-Authors

Carlos L. Arteaga
Carlos L. Arteaga The University of Texas Southwestern Medical Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Justin M. Balko
Justin M. Balko Vanderbilt University Medical Center
Aditya Bardia
Aditya Bardia Harvard University
Eric P. Winer
Eric P. Winer Yale University
Antonio C. Wolff
Antonio C. Wolff Johns Hopkins University
Timothy J. Whelan
Timothy J. Whelan McMaster University
Joseph A. Sparano
Joseph A. Sparano Albert Einstein College of Medicine
Ian E. Krop
Ian E. Krop Harvard University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in Medicine doesn’t always follow a single traditional path. Numerous related online degree programs and career options can help you advance or specialize in healthcare. For instance, if you’re a registered nurse seeking to become a Family Nurse Practitioner, asn to fnp programs offer flexible online bridge options. These programs are designed to help you progress efficiently from an ASN to an MSN and move into advanced practice roles.

Broader healthcare roles are also accessible online. For those interested in hospital or healthcare management, cahme accredited mha online programs provide quality training in administration, opening doors to leadership careers in the medical field.

Allied health careers like nutrition are in high demand. If you’re passionate about wellness and nutrition, a nutritionist online degree can be the first step to becoming a certified nutrition specialist or consultant, all from the convenience of your home.

Nurses seeking to upgrade qualifications should also explore rn to bsn online no clinicals programs, which offer even more flexible advancement for working professionals without the need for additional clinical hours. These diverse online choices make healthcare career growth more accessible than ever.

Best Scientists Citing Ingrid A. Mayer

Trending Scientists

Recently Published Articles